tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

STOK Stock Latest News

Buy Rating for Stoke Therapeutics: Promising Dravet Syndrome Treatment Shows Significant Improvements
RatingsBuy Rating for Stoke Therapeutics: Promising Dravet Syndrome Treatment Shows Significant Improvements
3d ago
STOK
Stoke Therapeutics, Biogen present data from EMPEROR study
PremiumThe Fly
Stoke Therapeutics, Biogen present data from EMPEROR study
4d ago
BIIB
STOK
Biogen, Stoke Therapeutics present data from studies of zorevunersen
PremiumThe Fly
Biogen, Stoke Therapeutics present data from studies of zorevunersen
4d ago
BIIB
STOK
Stoke Therapeutics files $400M mixed securities shelf
PremiumThe Fly
Stoke Therapeutics files $400M mixed securities shelf
5d ago
STOK
Positive Outlook on Stoke Therapeutics: Buy Rating Affirmed Amid Promising Phase 3 Trial for Dravet Syndrome Treatment
PremiumRatings
Positive Outlook on Stoke Therapeutics: Buy Rating Affirmed Amid Promising Phase 3 Trial for Dravet Syndrome Treatment
13d ago
STOK
Stoke Therapeutics Advances Phase 3 Study for Dravet Syndrome Treatment
PremiumCompany AnnouncementsStoke Therapeutics Advances Phase 3 Study for Dravet Syndrome Treatment
17d ago
STOK
Stoke Therapeutics Adopts Key Proposals at Annual Meeting
Premium
Company Announcements
Stoke Therapeutics Adopts Key Proposals at Annual Meeting
1M ago
8K
STOK
Stoke Therapeutics Launches Phase 3 EMPEROR Study
Premium
Company Announcements
Stoke Therapeutics Launches Phase 3 EMPEROR Study
1M ago
8K
STOK
Promising Outlook for Stoke Therapeutics: Buy Rating Backed by Phase 3 Trial Progress and Strong Financial Position
PremiumRatings
Promising Outlook for Stoke Therapeutics: Buy Rating Backed by Phase 3 Trial Progress and Strong Financial Position
2M ago
STOK
Stoke Therapeutics price target lowered to $35 from $47 at H.C. Wainwright
PremiumThe Fly
Stoke Therapeutics price target lowered to $35 from $47 at H.C. Wainwright
2M ago
STOK
Stoke Therapeutics’ Zorevunersen: A Promising First-in-Class Therapy for Dravet Syndrome with Strong Commercial Potential
PremiumRatings
Stoke Therapeutics’ Zorevunersen: A Promising First-in-Class Therapy for Dravet Syndrome with Strong Commercial Potential
2M ago
STOK
Stoke Therapeutics: Strategic Positioning and Financial Health Drive Buy Rating Amid Upcoming Phase 3 Trial for Dravet Syndrome Treatment
PremiumRatings
Stoke Therapeutics: Strategic Positioning and Financial Health Drive Buy Rating Amid Upcoming Phase 3 Trial for Dravet Syndrome Treatment
2M ago
STOK
Stoke Therapeutics’ Promising Outlook: Buy Rating Backed by Zorevenersen’s Potential and Strong Financial Position
PremiumRatingsStoke Therapeutics’ Promising Outlook: Buy Rating Backed by Zorevenersen’s Potential and Strong Financial Position
2M ago
STOK
Stoke Therapeutics Advances with Strong Q1 2025 Results
Premium
Company Announcements
Stoke Therapeutics Advances with Strong Q1 2025 Results
2M ago
STOK
Stoke Therapeutics: Promising Future with Strategic Biogen Partnership and Strong Market Potential for Lead Asset
Premium
Ratings
Stoke Therapeutics: Promising Future with Strategic Biogen Partnership and Strong Market Potential for Lead Asset
2M ago
STOK
Stoke Therapeutics: Strong Financial Position and Strategic Advancements Justify Buy Rating
PremiumRatings
Stoke Therapeutics: Strong Financial Position and Strategic Advancements Justify Buy Rating
2M ago
STOK
Stoke Therapeutics reports Q1 EPS $1.90 vs. (57c) last year
PremiumThe Fly
Stoke Therapeutics reports Q1 EPS $1.90 vs. (57c) last year
2M ago
STOK
STOK Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
STOK Upcoming Earnings Report: What to Expect?
2M ago
STOK
Stoke Therapeutics remains significantly undervalued, says Canaccord
PremiumThe Fly
Stoke Therapeutics remains significantly undervalued, says Canaccord
4M ago
STOK
Stoke Therapeutics: Buy Rating Affirmed Amid Strategic Developments and Strong Financial Position
PremiumRatingsStoke Therapeutics: Buy Rating Affirmed Amid Strategic Developments and Strong Financial Position
4M ago
STOK
Stoke Therapeutics Advances with Strong Financial Position
Premium
Company Announcements
Stoke Therapeutics Advances with Strong Financial Position
4M ago
STOK
Optimistic Buy Rating for Stoke Therapeutics Driven by Promising Clinical Trials and Strategic Developments
Premium
Ratings
Optimistic Buy Rating for Stoke Therapeutics Driven by Promising Clinical Trials and Strategic Developments
4M ago
STOK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >